Log In
BCIQ
Print this Print this
 

CD22-4AP

  Manage Alerts
Collapse Summary General Information
Company Catalent Inc.
DescriptionHumanized mAb conjugated to a toxin payload
Molecular Target CD22
Mechanism of Action 
Therapeutic Modality 

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/04/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today